Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

Protecting Your Heart During Recovery

At a Glance

After viral dilated cardiomyopathy, heart pumping can improve during three to six months of prescribed treatment. Some patients use a LifeVest for temporary protection, while a permanent heart device or advanced heart failure evaluation depends on recovery and ongoing risk.

One of the most encouraging aspects of viral dilated cardiomyopathy (viral DCM) is that the heart has a remarkable capacity to heal. Because many patients see significant improvement in their heart’s pumping power after starting medication, doctors often take a “wait and see” approach before recommending permanent surgical devices for primary prevention [1][2]. This period of monitoring ensures that you do not receive an invasive treatment you may not ultimately need.

The 3-to-6 Month Waiting Period (Primary Prevention)

If your ejection fraction (LVEF) is 35% or lower, you are generally at a higher risk for dangerous heart rhythms. For newly diagnosed nonischemic cardiomyopathy, current medical guidelines typically recommend waiting at least three to six months after starting optimized Guideline-Directed Medical Therapy (GDMT) before deciding on a permanent Implantable Cardioverter-Defibrillator (ICD) [3][4].

An ICD is a small device placed under the skin that monitors your heart and delivers a life-saving shock if it detects a lethal rhythm. The reason for the delay is reverse remodeling: as your heart heals from the viral or inflammatory event, its shape can return to normal and its strength can increase. If your LVEF rises above 35% during this window, you may no longer meet the primary criteria for a permanent ICD [5][2].
(Note: If you have already suffered a cardiac arrest, sustained ventricular tachycardia, or have specific high-risk genetic conditions, this waiting period does not apply and you may receive an ICD for secondary prevention immediately).

The Wearable Bridge: The LifeVest

To help keep selected patients safe during this three-to-six-month waiting period, or if an ICD indication is not yet established, your doctor may consider a Wearable Cardioverter-Defibrillator (WCD), often known by the brand name LifeVest [6].

  • How it works: This is a vest worn under your clothes that contains sensors and electrodes. If it detects a dangerous rhythm, it can deliver a shock to restore a normal heartbeat [7].
  • The Goal: It acts as a selective “bridge,” providing protection while your medical team evaluates how well your heart is responding to medication. It is not an automatic safety measure for every patient with an LVEF ≤35% [7][8].
  • The Commitment: For a WCD to be effective, it must be worn nearly 24 hours a day, only being removed for short showers [9].

Syncing the Beat: Cardiac Resynchronization Therapy (CRT)

In some cases of viral DCM, the heart’s electrical signals become uncoordinated. This is often seen on an EKG as a wide QRS interval or a Left Bundle Branch Block (LBBB) [10][11].

Cardiac Resynchronization Therapy (CRT) uses a specialized pacemaker to “resynchronize” the chambers, ensuring they pump together efficiently. CRT is usually considered when you have a persistently low LVEF, remain symptomatic despite optimal medical therapy, and meet specific EKG criteria for electrical delay [10]. For appropriately selected patients, CRT can lead to dramatic improvements in heart function [12][13].

Advanced Safety Nets

For most patients, medication and time are the keys to recovery. However, if the heart does not respond to standard treatments, early referral to an Advanced Heart Failure Center serves as a vital safety net. This evaluation should happen before a patient is in a severe crisis [14].

Your care team may consider an early referral if they see triggers such as:

  • Intolerance of GDMT: Inability to take standard heart medications because of low blood pressure or kidney function [15][16].
  • Escalating Diuretics: Needing increasingly higher doses of water pills to manage swelling and congestion [17][18].
  • Recurrent Hospitalizations or Arrhythmias: Frequent admissions for fluid buildup or dangerous rhythms [15][19].

These centers can evaluate you while you are still stable and provide long-term support options, such as a Left Ventricular Assist Device (LVAD)—a mechanical pump used as a bridge to transplant or destination therapy—or a heart transplant. Evaluation at an advanced center does not mean you will automatically need these therapies; it preserves your options and optimizes your care [19][20].

Common questions in this guide

Why do doctors usually wait three to six months before deciding on a permanent ICD?
In viral dilated cardiomyopathy, heart pumping strength may improve during three to six months of optimized medical treatment as the heart heals. If the ejection fraction rises above 35%, a permanent ICD for primary prevention may no longer be needed. This waiting period does not apply after cardiac arrest, sustained ventricular tachycardia, or certain high-risk genetic conditions.
What is a LifeVest, and who might use one during recovery?
A LifeVest is a wearable cardioverter-defibrillator worn under clothing that senses dangerous rhythms and can deliver a shock. It may be considered for selected people with a low ejection fraction while the care team evaluates whether medication improves heart function. It is not automatically recommended for everyone with an ejection fraction of 35% or lower.
How long should I wear a LifeVest each day?
For it to provide protection, a LifeVest should be worn nearly 24 hours a day and removed only for short showers. Removing it for longer periods can reduce the protection it provides.
When might cardiac resynchronization therapy be recommended?
CRT may be considered when the ejection fraction remains low, symptoms continue despite optimal medical treatment, and an EKG shows electrical delay such as a wide QRS interval or left bundle branch block. In appropriately selected patients, it can help the heart chambers pump together more efficiently and improve heart function.
When should I ask about an advanced heart failure center?
Ask about an early referral if you cannot tolerate standard heart medicines because of low blood pressure or kidney problems, need increasing doses of diuretics, or have repeated hospitalizations or dangerous rhythms. An evaluation does not mean you will need an LVAD or transplant; it can preserve options and help plan care before a crisis.
How will doctors tell whether my heart is recovering?
Doctors monitor changes in ejection fraction, symptoms, and your ability to tolerate treatment. Improvement in the heart’s pumping strength and shape is called reverse remodeling and may change whether a permanent device is needed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current LVEF, am I a candidate for a wearable cardioverter-defibrillator (LifeVest) while we wait for my medications to work?
  2. 2.Why is it important for me to wait at least three to six months before considering a primary-prevention permanent ICD?
  3. 3.Does my EKG show a specific wide QRS interval or pattern that, combined with my symptoms, makes me a candidate for CRT?
  4. 4.How will we know if my heart is 'remodeling' or recovering enough to avoid a permanent device?
  5. 5.If my symptoms worsen or I struggle to tolerate my medications, at what point should we consider a referral to a specialized advanced heart failure center?
  6. 6.What are the specific 'triggers' or signs in my blood work (like kidney or liver function) that would indicate I need more advanced support?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.

    Duncker D, König T, Hohmann S, et al.

    Journal of the American Heart Association 2017; (6(1)) doi:10.1161/JAHA.116.004512.

    PMID: 28096098
  2. 2

    Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.

    Veltmann C, Duncker D, Doering M, et al.

    European heart journal 2024; (45(30)):2771-2781 doi:10.1093/eurheartj/ehae334.

    PMID: 38864173
  3. 3

    The Heart Failure Optimization Study (HF-OPT): rationale and design.

    Sanchez R, Duncker D, Colley B, et al.

    Herzschrittmachertherapie & Elektrophysiologie 2023; (34(1)):52-58 doi:10.1007/s00399-022-00920-5.

    PMID: 36695885
  4. 4

    The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape.

    Wong JA, Roberts JD, Healey JS

    The Canadian journal of cardiology 2021; (37(4)):644-654 doi:10.1016/j.cjca.2021.01.024.

    PMID: 33549824
  5. 5

    Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period.

    Waezsada E, Hutter J, Kahle P, et al.

    Journal of clinical medicine 2022; (11(20)) doi:10.3390/jcm11206122.

    PMID: 36294443
  6. 6

    Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.

    Lamichhane M, Safadi A, Surapaneni P, et al.

    Current cardiology reports 2016; (18(8)):78 doi:10.1007/s11886-016-0746-5.

    PMID: 27319008
  7. 7

    When is a wearable defibrillator indicated?

    Bodin A, Bisson A, Fauchier L

    Expert review of medical devices 2021; (18(sup1)):51-56 doi:10.1080/17434440.2021.2019013.

    PMID: 34913789
  8. 8

    Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management.

    Ali-Ahmed F, Dalgaard F, Al-Khatib SM

    American heart journal 2020; (220()):29-40 doi:10.1016/j.ahj.2019.08.007.

    PMID: 31765933
  9. 9

    Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry.

    Odeneg T, Ebner C, Mörtl D, et al.

    European journal of cardiovascular nursing 2019; (18(1)):75-83 doi:10.1177/1474515118790365.

    PMID: 30064269
  10. 10

    Multidisciplinary approach to long-standing left bundle branch block with dyssynchrony and aortic stenosis: case report.

    Maigrot JA, Weiss AJ, Wazni O, Starling RC

    European heart journal. Case reports 2024; (8(4)):ytae127 doi:10.1093/ehjcr/ytae127.

    PMID: 38567275
  11. 11

    Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.

    Friedman DJ, Al-Khatib SM, Dalgaard F, et al.

    Circulation 2023; (147(10)):812-823 doi:10.1161/CIRCULATIONAHA.122.062124.

    PMID: 36700426
  12. 12

    New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study.

    Wang NC, Singh M, Adelstein EC, et al.

    Heart rhythm 2016; (13(4)):933-42.

    PMID: 26688064
  13. 13

    New strict left bundle branch block criteria reflect left ventricular activation differences.

    Emerek K, Risum N, Hjortshøj S, et al.

    Journal of electrocardiology 2015; (48(5)):758-62.

    PMID: 26233647
  14. 14

    Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

    Fang JC, Ewald GA, Allen LA, et al.

    Journal of cardiac failure 2015; (21(6)):519-34.

    PMID: 25953697
  15. 15

    Patient Selection for Destination LVAD Therapy: Predicting Success in the Short and Long Term.

    Michaels A, Cowger J

    Current heart failure reports 2019; (16(5)):140-149 doi:10.1007/s11897-019-00434-1.

    PMID: 31240639
  16. 16

    Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.

    Crespo-Leiro MG, Metra M, Lund LH, et al.

    European journal of heart failure 2018; (20(11)):1505-1535 doi:10.1002/ejhf.1236.

    PMID: 29806100
  17. 17

    Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy.

    Acharya D, Sanam K, Revilla-Martinez M, et al.

    The American journal of cardiology 2016; (117(6)):952-6.

    PMID: 26810859
  18. 18

    Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure.

    Hashim T, Sanam K, Revilla-Martinez M, et al.

    Circulation. Heart failure 2015; (8(5)):880-6 doi:10.1161/CIRCHEARTFAILURE.114.001778.

    PMID: 26179184
  19. 19

    Role of Durable Mechanical Circulatory Support for the Management of Advanced Heart Failure.

    Waqas M, Cowger JA

    Heart failure clinics 2016; (12(3)):399-409.

    PMID: 27371516
  20. 20

    Trajectories following Impella 5.5 support are associated with initial presentation acuity.

    Maigrot JA, Starling RC, Soltesz EG, et al.

    Artificial organs 2025; (49(1)):137-145 doi:10.1111/aor.14867.

    PMID: 39422190

This page is for informational purposes only and does not constitute medical advice. Your cardiology team should decide whether a LifeVest, ICD, CRT, or advanced heart failure referral is appropriate for your situation.

Get notified when new evidence is published on viral dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.